FRIDAY, MAY 14, 2021 INAUGURAL MEETING: VIRTUAL FORMAT COURSE DIRECTORS GINI FLEMING, MD | UNIVERSITY OF CHICAGO MEDICINE DIANE YAMADA, MD | UNIVERSITY OF CHICAGO MEDICINE KATHERINE KURNIT, MD, MPH | UNIVERSITY OF CHICAGO MEDICINE CHICAGO GYN ONCOLOGY UPDATES
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
FRIDAY, MAY 14, 2021INAUGURAL MEETING: VIRTUAL FORMAT
COURSE DIRECTORSGINI FLEMING, MD | UNIVERSITY OF CHICAGO MEDICINEDIANE YAMADA, MD | UNIVERSITY OF CHICAGO MEDICINEKATHERINE KURNIT, MD, MPH | UNIVERSITY OF CHICAGO MEDICINE
C H I C A G OGYN ONCOLOGY
U P D A T E S
LEARNING OBJECTIVESAt the conclusion of this activity, participants will be able to:
·· Define the mechanisms of action and side effect profiles of new gynecologic cancer therapies;
·· Discuss how to apply recent PARP inhibitor research to front-line therapy of ovarian cancer;
·· Describe how to select ovarian cancer patients for maintenance therapy with PARP inhibitors and for antiangiogenic therapy;
·· Identify strategies to explain to patients the efficacy results of immunotherapy and immunotherapy/antiangiogenic combination therapy in endometrial cancer;
·· Determine the sequencing and combination of new agents used for gynecologic cancer care with current therapies;
·· Identify contextual barriers to the integration of new gynecologic cancer agents into patient care;
·· Recall how to overcome barriers to recruit underserved populations for clinical trials;
·· Select appropriate tumor genomic tests for gynecologic cancer patients.
TARGET AUDIENCEThis activity is designed for gynecologic oncologists, medical oncologists, radiation oncologists, gynecologists, trainees, research scientists, nurses, nurse practitioners, physician assistants, and other healthcare professionals dedicated to the care of patients with gynecologic malignancies.
PHYSICIAN CREDITThe University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide
continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CREDITUniversity of Chicago Medicine is approved as a provider of nursing continuing professional development by the Ohio Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. (OBN-001-91)
This live activity is designated for a maximum of 3.25 continuing nursing education units.
AMERICAN BOARD OF INTERNAL MEDICINE MOC PART II CREDITSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
OTHER HEALTHCARE PROFESSIONALS CREDITOther healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
COURSE DESCRIPTION
Chicago GYN Oncology Updates will celebrate contributions of SGO members, providing
access to the most important educational and scientific updates for women’s healthcare
professionals from the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s
Cancer. This conference will include information and resources for members of the entire
gynecologic cancer care team who provide treatment and care in the areas of chemotherapy,
radiation therapy, and surgery. This highly interactive program will provide participants with
distillations of advances in the fields of ovarian cancer and endometrial cancer. Topics will
include both appropriate use of new therapies including immunotherapy, antiangiogenic
agents, and PARP inhibitors, as well as information on appropriate use and applications of
genomic testing. In addition, the critical importance of clinical research will be highlighted
with presentations of Chicago area investigator-initiated trials and information regarding the
importance of and suggestions for inclusion of underserved populations in clinical research.
INFORMATION
FACULTY
COURSE DIRECTORSGini Fleming, MD Professor of Medicine
PATIENT REGISTRATION: COMPLIMENTARY - Reach out to [email protected]
HOW TO REGISTER ONLINE – (credit card payment only)
cme.uchicago.edu/GynOncUpdates2021
CANCELLATION POLICY If you cancel your participation in this conference, your registration fee less a 50% administrative fee will be refunded when written notification is received by April 14, 2021. No refunds will be made after April 14, 2021.
ADDITIONAL INFORMATION For information regarding course, contact [email protected].
REGISTRATION
cme.uchicago.edu/GynOncUpdates2021
DISCLOSURE DECLARATIONSAs a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks
everyone who is in a position to control the content of an education activity to disclose all relevant
financial relationships with any commercial interest. This includes any entity producing, marketing,
re-selling, or distributing health care goods or services consumed by or used on patients.
The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring
within the past 12 months, including financial relationships of a spouse or life partner that could create a
conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior
to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires authors to identify
investigational products or off-label uses of products regulated by the US Food and Drug Administration,
at first mention and where appropriate in the content.